Ying Hu

PhD, Professor
Phone: 86-0451-86403992
Email: huying@hit.edu.cn
Research Area:Biological functions and regulations of proto-oncogene and tumor suppressor
Lab Home:http://slst.hit.edu.cn/research/labs/gene-function-lab

Ying HU is a cancer cell biologist who has severed on the School of Life Science and Technology in HIT as a professor since 2012. Dr. HU earned her B.S. in the Public health at Shandong Medical University in 1999 and M.S. in Biochemistry and molecular biology at Fudan University Medical School i n 2002. She worked i n the Princess Wales Hospital, the Chinese University of Hongkong from 2002-2004 and received her Ph.D. in Cancer Biology at University College London (UCL), UK in 2009. Since then, she worked at Oxford University as a biologist and postdoctoral fellow until she joined HIT.

Her research mainly focused on cancer biology specifically in the field of drug response and cancer metastasis. p53 is the most frequently-mutated gene in human tumors. Over 50% of all tumors and almost every type of tumor contain p53 mutations, whereas wild type p53 tumors are often accompanied with the defects in p53 signaling components. No doubt, revealing p53’s functions and its regulatory mechanisms is critical for understanding the molecular mechanisms of oncogenesis. Dr. HU’s research interest is to investigate p53 signaling and particularly to dissect the interactions of p53 family members with other upstream regulatory proteins, such as ASPPs. The research in the lab is carried out at molecular and cellular levels using both cancer cells models and clinical human cancer tissue samples. The methods and technologies used in her current lab include in vitro cell culture, MTT, Western Blotting, FACS, RT-PCR, molecular cloning, soft agar assay and many other molecular and cellular tools. The goal of laboratory is to develop clinically relevant biomarkers and therapeutic targets for human malignancy diseases. 

Selected Publications:

1. Wang Xingwen, Cheng Yiwei, Zhu Yifu, Li Huayi, Ge Wenjie, Wu Xiaoliang, Zhao Kunming, Yuan J, Li

   Z, JiangS, Han Zhengbin, Jiang Qinghua, Wu Qiong, Liu Tao, Zhang Cheng*, Yu Miao*,Hu Ying*.

   EpigeneticSilencing of ASPP1 confers 5-FU resistance in Clear Cell Renal Cell Carcinoma by preventing

   p53 activation.Int J Cancer. 2017 Jun 28. doi: 10.1002/ijc.30852.（* corresponding author）

2. Kunming Zhao, Miao Yu, Yifu Zhu, Dong Liu, Qiong Wu, andYing Hu*. EGR-1/ASPP1 inter-regulatory

   looppromotes apoptosis by inhibiting cyto-protective autophagy. Cell Death Dis. 2017 Jun 8;8(6):e2869.

   doi:10.1038/cddis.2017.268.（*corresponding author）

3. Wang Xingwen Wang, Miao Yu,Kunming Zhao, Mengmeng He,Wenjie Ge,Yuhui Sun,Yihua Wang,Haizhu

   Sun,Ying Hu*. Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by

   targeting ASPP2. Cell Death Dis. 2016 Dec 8;7(12):e2517. doi: 10.1038/cddis.2016.412.（*corresponding

   author）

4. Ying Hu*, Wenjie Ge, Xingwen Wang, Gopinath Sutendra, Kunming Zhao, Zinaida Dedeić, Elizabeth A.

   Slee,Caroline Baer and Xin Lu*. Caspase cleavage of iASPP potentiates its ability to inhibit p53 and NFκB.

   Oncotarget.2015 Dec 15;6(40):42478-90. doi: 10.18632/oncotarget.6478.（*corresponding author）

5. L.N. Shao，S. T. Zhang，W. J. Yu，S. H. Zhou，Y. Duan，L. Z. Pan，N. Wang，Ying Hu*，HLA-A,

   HLA-B,HLA-DRB1 allele and haplotype frequencies of 14,529 Chinese Han bone marrow donors living in

   Dalian,China.，International Journal of Immunogenetics DOI:10.1111/iji.12248，2016，Epub ahead（of

   print）（* corresponding author）

6. Sun H, Ge W,Gao X, Wang S, Jiang S,Ying Hu*, Yu M* , Hu S*. Apoptosis- Promoting Effects of Hematoporphyrin Monomethyl Ether- Sonodynamic Therapy (HMME-SDT) on Endometrial Cancer. PLoS One. 2015 Sep 14;10(9):e0137980.（* corresponding author）

7. Mario Notari#，Ying Hu#，Sofia Koch，Min Lu， Indrika Ratnayaka，Shan Zhong，Caroline Baer，Anna Pagotto，Robert Goldin，Victoria Salter，Eleonora Candi，Gerry Melino，and Xin Lu*. iASPP prevents premature cellular senescence and is required for normal epithelial stratification. Proc Natl Acad Sci. 2011. 108(40): 16645–16650.（# co-first author）

8. Mario Notari，Ying Hu，Gopinath Sutendra, Zinaida Dedeic, Min Lu, Laurent Dupays, Arash Yavari, Carolyn Carr, Shan Zhong, Aaisha Opel, Andrew Tinker, Kieran Clarke, Hugh Watkins, David Ferguson, David Kelsell, Sofia de Noronha, Mary Sheppard, Mike Hollinshead, Timothy J Mohun and Xin Lu*. iASPP: A Novel Desmosome Regulator and its Deficiency Causes Arrhythmogenic Right Ventricular Cardiomyopathy. Proc Natl Acad Sci. 2015. Feb 17. pii: 201408111.

9. Min Lu, Hilde Breyssens，Victoria Salter，Shan Zhong，Ying Hu，Caroline Baer，Indrika Ratnayaka，Alex Sullivan，Nicholas R Brown，Stefan Knapp，Benedikt Kessler,Mark R Middleton，Christian Siebold，Yvonne Jones，Elena V Sviderskaya，Jonathan Cebon，Tom John，Otavia Caballero，Colin R Goding and Xin Lu*. Restoring p53 function in human melanoma cells by inhibiting mdm2 and cyclinB1/cdk1 phosphorylated nuclear iASPP. Cancer cell. 2013. 23(5):618-33.

10. Zhenglin Li, J Liu,Ying Hu, Z Li, Fan X, Sun Y Miao Yu. Biocompatible PEGylated bismuth nanocrystals: All-in-one theranostic agent with triple-modal imaging and efficient in vivo photothermal ablation of tumors.Biomaterials. 2017 Jun 23;141:284-295.

11. Zhenglin Li, Jing Liu,Ying Hu, Kenneth A. Howard, Zhuo Li, Xuelei Fan, Manli Chang, Ye Sun,*Flemming Besenbacher,* Chunying Chen,Miao Yu*, Multimodal imaging-guided antitumor photothermal therapy and drug delivery using bismuth selenide spherical-sponge, ACS Nano, 2016, 10, 9646-9658.

12. Zhenglin Li,Ying Hu, Manli Chang, Kenneth A. Howard, Xuelei Fan, Ye Sun,* Flemming Besenbacher*, Miao Yu*, Highly porous PEGylated Bi2S3 nano-urchins as a versatile platform for in vivo triple-modal imaging, photothermal therapy and drug delivery, Nanoscale, 2016, 8,16005-16016.

13. Zhenglin Li,Ying Hu, Howard KA, Jiang T, Fan X, Miao Z, Sun Y*, Besenbacher F*,Yu M* Multifunctional 

     Bismuth Selenide Nanocomposites for Antitumor Thermo-Chemotherapy and Imaging. ACS Nano. 2015 Dec 1.